Earlier this year, Charles River Laboratories acquired SAMDI Tech, a provider of proprietary mass spectrometry technology that enables label-free, high-throughput screening for drug discovery. The technology cuts cost and accelerates the time it takes to identify a lead drug candidate, enabling drug developers to make critical go-no-go decisions earlier. We spoke to Zack Gurard-Levin, science director in discovery for Charles River Laboratories about the advantages SAMDI’s mass spectrometry offers over alternative technologies, how it enables the study of a broad range of modalities, and how it fits into a comprehensive set of Charles River offerings.
